Novel transgenic technology reveals several molecular adaptations and potential therapeutic targets in the direct pathway in levodopa-induced dyskinesia

Movement Disorders

Volumn 29, Issue 6, 2014, Pages 721-

  Visanji, Naomi P ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; MITOGEN ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1;

ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CDK11B GENE; CSTB GENE; DISEASE SEVERITY; DYSKINESIA; FNDC9 GENE; FOSL1 GENE; GENE; GENE EXPRESSION; GPR39 GENE; IER3 GENE; ITCH GENE; LEVODOPA INDUCED DYSKINESIA; MOLECULAR BIOLOGY; NONHUMAN; NR4A2 GENE; PATHOGENESIS; PRIORITY JOURNAL; SCP2 GENE; SRXN1 GENE; TINF2 GENE; UPREGULATION; ANIMAL; CORPUS STRIATUM; DRUG EFFECTS; GENETICS;

ANIMALS; CORPUS STRIATUM; DYSKINESIA, DRUG-INDUCED; LEVODOPA;

EID: 84899856993     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25906     Document Type: Article

References (2)

1. Heiman M, Schaefer A, Gong S, et al. A translational profiling approach for the molecular characterization of CNS cell types. Cell 2008;135:738-748.
2. Heiman M, Heilbut A, Francardo V, et al. Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia. Proc Natl Acad Sci U S A 2014 Mar 5. doi: 10.1073/pnas.1401819111. [Epub ahead of print].